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Background: Clinical and functional outcome improvement in psychotic disorders is a
challenge for the investigators. Recent advances offered opportunities for ameliorating
the course of the illness during its early stages and for identifying treatment-resistant
patients. Patients who had not response to two different antipsychotics, administered at
correct doses for a sufficient period, can be operationally considered treatment-resistant.
Available evidence suggested that the response’s trajectory to the antipsychotic
treatment revealed that a small proportion of subjects are poor responders (8.2%),
the majority of patients have a moderate response (76.4%), and only 15.4% can be
considered rapid responders with the greatest magnitude of response. Patients with first
episode of psychosis generally obtain a more favorable response profile. Nevertheless,
in around 25% of these patients symptoms of psychosis persist with a worse long-term
course of illness.
Objectives: The aim of this review is to report current evidences on the main predictors
of treatment non-response in patients at early stage of psychosis.
Methods: We used a specific string that guaranteed a high sensitive search in
pubmed. We included the following types of publications: randomized-controlled trials,
observational studies, longitudinal studies, retrospective studies, case-control studies,
open-label investigations, cohort studies, and reviews. Publications must concern
predictors of treatment resistance in early psychosis.
Results: Forty-seven records were included: 5 reviews, 3 meta-analyses, 22 longitudinal
studies, 2 retrospective studies, 1 naturalistic study, 6 randomized controlled trials, 2
open-label studies, 2 case-control studies, 4 cohort studies, 2 retrospective studies.
Several factors were identified as predictors of treatment resistance: lower premorbid
functioning; lower level of education; negative symptoms from first psychotic episode;
comorbid substance use; younger age at onset; lack of early response; non-adherence
to treatment; and longer duration of untreated psychosis. The role of gender and marital
status is still controversial. More evidences are needed about neurobiological, genetic,
and neuroimaging factors.
Conclusions: The identification of specific predictive factors of treatment resistance in
patients with first episode of psychosis ameliorates the quality of clinical management of
these patients in the critical early phase of schizophrenia.
Keywords: schizophrenia, first episode of psychosis, treatment resistance, non-response, predictors of response,
clinical factors, biological factors
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INTRODUCTION
The point prevalence estimated for schizophrenia is around 0.6–
0.8% and the lifetime prevalence is about 1%. In general, first
psychotic episode starts in young adulthood, but the onset of
the disorder is preceded by a variety of prodromal symptoms
(1–4). There is a general accordance among investigators that
treatment response in schizophrenia is very heterogeneous (5,
6). “Treatment outcome has been extensively studied in first-
episode schizophrenia. However, the majority of investigations
have mainly focused on favorable outcome measures such as
response, remission and recovery” (7). Although a good number
of patients obtain the remission of symptoms, a significant
percentage of cases remains “actively and persistently psychotic
despite correct pharmacological treatments” (8). Nevertheless,
whether the resistance to treatments is present from the onset
of illness (first episode of psychosis-FEP) or whether patients
gradually become resistant due to the disease progress is still
little known today (8). Some authors state that “patients with
FEP may show long-term incomplete remission or treatment
resistance in a percentage ranged between 10 to 50%” (9–11).
Outcomes in first-episode psychosis (FEP) vary on a continuum
from complete remission and full recovery to complete failure
of response or treatment resistance. A possible reason of this
variability is the intrinsic diagnostic instability of patients at first
episode of psychosis.
Resistance to treatments represent a critical topic in
schizophrenia spectrum disorders as it is linked with an higher
risk of a clinical deterioration, hospitalizations, chronicity,
neurotoxic effects of relapses, suicide, aggressive conducts, poor
quality of life, and low level of real-world functioning (7, 8, 12–
16). Clinical, social, and vocational recovery failure increases
the economic cost and enhances burden for family members
and stigma for patients (11). Available evidences suggest that
the trajectory of response to the antipsychotics treatment reveals
that a small proportion of subjects are poor responders (8.2%),
the majority of patients have a moderate response (76.4%),
and only 15.4% can be considered rapid responders with the
greatest magnitude of response (17). Patients with FEP generally
obtain a more favorable response profile than patients after
multiple episodes. Nevertheless, in around 25% of these patients
symptoms of psychosis persist with a worse long-term course
of illness (17–22). The precocious identification of individuals
who fail to respond to initial interventions may ameliorate
the treatment approach at an earlier phase of illness to avoid
multiple, unnecessary switches or repeated medication trials
and to prevent accruing morbidity. Specialized integrated early
interventions, including antispychotics, individual psychological
treatment, family, and vocational support are shown to be
effective to improve treatment response (23). Unfortunately,
as regards the predictive factors of treatment resistance in
early phase of illness, the literature to date is still sparse and
inconclusive. The present review is aimed to provide an updated
overview of current evidences on the main predictive factors of
non-response and treatment resistance in patients at early stage
of psychosis.
TREATMENT NON-RESPONSE AND
TREATMENT-RESISTANCE: DEFINITIONS
Investigations indicated that response to antipsychotic
treatments begins in the first weeks of treatment with the
largest effect in reducing symptoms in the first 2 weeks (17, 24).
Remission was defined as “a state, of at least 6 months’ duration,
in which no symptoms or only mild symptoms, not interfering
with daily functioning, were experienced” (25). Early non-
response was operationally defined as “<20% improvement
on Positive and Negative Symptoms Scale (PANSS) or Brief
Psychiatric Rating Scale (BPRS) total score at 2 weeks” (26).
Some authors suggested that “patients who have not a minimal
improvement after 2 weeks of treatment are unlikely to respond
at a later phase and may benefit from a drug change” (26, 27).
Kane et al. (28) defined treatment resistance with three
criteria. “First, the patient fails to respond to three or more
adequate trials of antipsychotic treatment within the last 5
years, including antipsychotics of two distinct classes at dose
greater than or equal to the equivalent of 1,000 mg/day of
chlorpromazine.” Moreover, it is widely accepted that three or
more second generation antipsychotics failures define treatment
resistance (29). “Second, at least two of the symptoms of
conceptual disorganization, suspiciousness, hallucinations, and
unusual thought content persist with a score at least moderate
in severity. Lastly, patient has evidence of substantial symptoms
despite current optimized treatment to which the patient is
adherent, defined as a score ≥45 on the BPRS or ≥90 on the
PANSS” (28).
In line with the National Institute for Health and Care
Excellence (NICE) (2) criteria, “patients who had received two
sequential antipsychotic trials, each of at least 4 weeks at a
daily dose of 400–600mg of chlorpromazine equivalents, but
continued to have persistent psychotic symptoms, which was
defined as having a rating of at least moderate severity on one
or more positive symptoms, and despite recorded adherence
to medication, were classified as treatment resistant. Patients
were classified as treatment resistant at onset if they met
criteria for treatment resistance following the first two trials with
antipsychotics” (2).
Although the definition of the treatment resistance is mainly
centered on clinical symptoms’ relief, several authors suggested
to include the evaluation of psychosocial elements, such as
adherence to medications, and daily functional outcome in
the context of resistance definition. In this view, patients can
be considered resistant to therapy only if both clinical and
functional outcome are compromised (30–32).
A recent review performed by the treatment-resistant
schizophrenia working group consensus guidelines (33)
concluded that there was a relative consensus among authors
in defining subjects treatment-resistant: a confirmed diagnosis
of schizophrenia based on validated criteria, an adequate
pharmacological treatment, and the persistence of significant
symptoms despite adequate treatment (33). Although significant
differences exist among the main guidelines for the treatment
of schizophrenia in terms of operationalized definition of
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resistance, some commonalities can be observed. In particular,
the shared criteria concern the requirements for at least two
failed treatment trials, each of a minimum of 6 weeks, and the use
of standardized rating scales (2, 34–38). In addition, the working
group consensus guidelines (33) suggested to incorporate into
criteria for defining treatment-resistance two further elements:
patients adherence and functional impairment.
METHODS
In April 2018, we performed an electronic search in PubMed
on predictive factors of treatment resistance in FEP, with no
filter or MESH restriction, using the following search string:
“schizophrenia” OR “psychosis” OR “first-episode of psychosis”
OR “early psychosis” AND “predictive factors” OR “predictors
of response” AND “resistant patients” OR “treatment resistance”
OR “treatment non-response.” This string provided a high
specific search, obtaining an accurate selection of article indexed
in PubMed. We included the following types of publications:
randomized-controlled trials, observational studies, longitudinal
studies, retrospective studies, case-control studies, open-label
investigations, cohort studies, and reviews until July 2018.
Publications must concern predictors of treatment resistance
in early psychosis as the principal issue (all definitions of
resistance described in the previous paragraph are included in
our revision). We excluded publications written in languages
different from English.
RESULTS
The search described in the previous section provided 1208
records. Eighty additional records were identified from another
research platform (Google scholar). We removed the duplicates
records (246). Eligibility status for all retrieved articles was
determined in two stages. First, all studies were screened basing
upon title and abstract. Second, papers passing the initial title and
abstract screen were reviewed basing upon the full manuscript.
Nine hundred seventy-seven records were excluded because they
did not fit the objective of the review, 11 as the full text was not
available. Full text articles selected for eligibility were 54; seven of
them were excluded as were not written in English. This review
included 47 records: 5 reviews, 3 meta-analyses, 22 longitudinal
studies, 2 retrospective studies, 1 naturalistic study, 6 randomized
controlled trials, 2 open-label studies, 2 case-control studies, 4
cohort studies.
Number of studies participants was ranged between 56 and
1,175. All studies included both genders; the majority of studies
had an equal distribution of males and females. The predominant
ethnicity was the Caucasian. Duration of the longitudinal studies
was ranged between 1 and 10 years, while the duration of
controlled-trials was ranged between 6 weeks (acute phase) and
1 year. Ninety percent of studies enrolled participants at early
stage of illness (first episode of psychosis, first hospital contact,
recent onset of psychosis). All subjects presented a schizophrenia
spectrum disorder. The PRISMA flow chart of this review is
presented in Figure 1.
Patient-Related Predictors of Treatment
Resistance
Predictors of treatment resistance that are linked to patients
characteristics were investigated in recent years. In particular age,
gender, premorbid functioning, level of education, and marital
status are the main individual-related factors that were studied in
the context of resistance to treatment.
Crespo-Facorro et al. (40) performed a randomized controlled
study, in which 172 patients with a first episode of non-
affective psychosis were assigned to haloperidol, olanzapine,
and risperidone in a random way. Results concerned the “6-
weeks acute phase of a large epidemiological and longitudinal
(3 years) intervention program of first-episode psychosis” (40).
Among the patient-related variables, authors found that lower
premorbid functioning was one of the most important factors
in distinguishing antipsychotic non-responders from responders.
This result was confirmed in a second study conducted by
the same authors (41) on 375 FEP subjects. Similar findings
were also reported by Addington and Addington (42) in 240
schizophrenia spectrum disorder patients with FEP in a period
of follow-up of 36 months, and by Albert et al. (43) in a 5-years
study including 255 FEP patients. Several investigations adequate
for sample characteristics and duration (44–47) suggested that
a good premorbid adjustment and social environment may
predict a better response to treatments. Recently, Lasalvia et al.
(48) confirmed this result stating that “premorbid adjustment
and insight predicted outcome regardless of the kind of
treatment” (48).
Wimberley et al. (49) performed a 9-years cohort study
(population-based) in 8624 patients with a diagnosis of
schizophrenia to identify predictive factors of treatment
resistance at first hospital contact. Results showed that “a
younger age, living in a less urban area, and primary education
level were all significantly associated with treatment-resistant
schizophrenia” (49). The relationship between lower educational
level and treatment resistance was previously found by other
three studies performed by Verma et al. (50), Díaz et al. (51), and
Lasalvia et al. (48) in samples of respectively, 1,175 subjects with
schizophrenia spectrum disorders, 174 patients with FEP, and
444 patients with schizophrenia. In a recent study published by
Di Capite et al. (52) evaluating predictors of relapse in 63 patients
with first-episode psychosis who have discontinued antipsychotic
medications in a period on 1 year, authors concluded that “to
be engaged in education or training was not predictive of
relapse” (52).
Only few studies found a relationship between age and
treatment-response, also due to the fact that many investigations
have not considered age but age at illness onset. Nevertheless,
two studies (43, 53) reported an association between older
age and remission. Study published by Zhang et al. lasted
1 year and included 398 patients never medicated with FEP
in schizophrenia spectrum disorders. The role of gender, in
particular male gender, as predictor of worse response to
treatments since the FEP is still controversial, although male
gender is traditionally retained an indicator of poor outcome in
schizophrenia. Some studies actually suggested that male gender
may be considered a predictor of treatment non-response in
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FIGURE 1 | PRISMA flow diagram. Adapted from Moher et al. (39).
FEP and schizophrenia spectrum disorders. In particular, Selten
et al. (54) performed a study with a follow-up phase lasting 30
months in 125 subjects with FEP and schizophrenia spectrum
disorders diagnosis. They found that the predominant predictor
of poor outcome was male gender (together with substance
abuse). Similar findings were reported by Derks et al. (55)
and Díaz et al. (51). The two study had a similar design, the
same duration of 1 year and the same criteria of inclusion:
patients with FEP in schizophrenia spectrum disorders, including
brief reactive psychosis and schizoaffective disorder. The only
significant difference concerned the sample size, as in the first
study were included 498 patients, while in the second they were
only 174. Lower odds for remission were found in male patients
in both studies. These findings were confirmed by the study
performed by Di Capite et al. (52) that suggested that males had
a higher risk of relapse after antipsychotic discontinuation then
females and in the study conducted by Lally et al. (56) in 246
FEP patients with schizophrenia spectrum disorders concluding
that treatment resistance was strictly connected with male sex.
Other investigations considered the female gender as one of
predictive factors of response to treatment. There was a broad
accordance among authors in retaining that the female sex
represents a strong predictor of remission and recovery (43, 50,
57). However, it must be noticed that many other studies have
not confirmed the effect of gender on response to treatments
(15, 19, 21, 44, 47, 58–64).
Data concerning the role of marital status in predicting
treatment resistance are scarce and heterogeneous. Emsley et al.
(45) found in a study of 1 year on 57 patients with FEP
and schizophrenia spectrum disorders a significant relationship
between single status and resistance to treatments. In a similar
way Díaz et al. (51) reported that single status predicted
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non-response and non-remission. On the contrary, Teferra et al.
(65) reported that single status may predict better outcome
in a 5-years study performed in Ethiopia in 312 patients
with schizophrenia.
Disorder-Related Predictors of Treatment
Resistance
With respect to clinical predictors of treatment resistance in FEP
several symptomatic factors have been discussed about treatment
resistance and poor long-term outcome. Positive symptoms were
thought for long time to be the most important outcomemeasure
and were the standard parameters for treatment resistance
assessment. This was due to the fact that other symptoms were
not correctly recognized or undervalued, or symptoms such as
negative symptoms were considered unresponsive to treatment.
Considering the clinical response only in terms of the positive
symptoms decrease is clearly reductive. In fact, schizophrenia
since its early stages includes a wider spectrum of symptoms,
involving negative, cognitive, and/or disorganized symptoms,
as well as functional deficits. Several authors have shown
that residual positive symptoms and global psychopathology,
cognitive impairment, and enduring negative symptoms
constituted the indicators of the severity of schizophrenia and
were associated with non-response to antipsychotics (66–68).
In an epidemiological cohort study lasting 18 months
and including 367 FEP patients “treated with olanzapine or
risperidone” (69), authors found that 33% of patients with
schizophrenia had continuous positive symptoms and another
22% presented positive symptoms following relapse. Overall, 35%
of patients were found to be in symptomatic remission at 18
months but 20% had persistent psychoses with an unchanged
severity of illness. Crespo-Facorro et al. (41) found that the
presence of positive and disorganized symptoms at baseline
predicted resistance to treatment. Addington andAddington (42)
stated that “the high level of both positive and negative symptoms
may predict poor outcome in schizophrenia spectrum disorders.”
Investigations focused on the evaluation of positive symptoms
of schizophrenia as poor response and resistance predictors
remain rather sparse. However, on this topic, an interesting
10-year follow-up study has been performed to investigate
“long-term trajectories of positive and negative symptoms in
FEP” (70). Four-hundred-ninety-six patients with diagnosis of
schizophrenia spectrum disorders were assessed with several
evaluation tools, such as the Scales for the Assessment of Positive
(SAPS) and Negative Symptoms (SANS) (71). Results indicated
that around 60% of subjects experienced a reduction followed
by a stabilization of positive symptoms during a period ranged
between one and 5 years, while changes in negative symptoms did
not reach the same degree. Moreover, in patients who responded
to treatment the trend of positive symptoms continued to
improve across 10 years. On the other hand, 50% of the cohort
did not obtain a reduction of negative symptoms over the 10 years
(70). Individuals who persistently suffer from negative symptoms
may present impaired functioning and psychological outcomes
with a higher rates of treatment resistance in comparison with
people who show a decrease of negative symptoms over time (72,
73). As negative symptoms are already present and prominent
at the early phase of the illness, in a minority of patients the
full syndrome of treatment resistance is present since the FEP.
Milev et al. (67) performed a longitudinal first-episode study
with a 7-year follow-up on 99 subjects who were in their first
episode of illness. Authors found a significant influence of both
cognitive and negative symptoms on response to treatments.
Similar findings were observed by Siegel et al. (74) in 208 patients
with schizophrenia monitored for 3 years.
Higher severity of negative symptoms at the beginning of the
trials was recognized to be a powerful predictor of resistance
to treatments also in more recent investigations. In particular,
Ventura et al. (75) showed that the degree of negative symptoms
in 149 recent-onset (1 year) subjects with schizophrenia was
associated with impaired everyday functioning 7 years later.
Negative symptoms in early psychosis did not change in the
first year and predicted social functioning after 12 months. In
addition, negative symptoms at onset of schizophrenia were
related to the persistence of negative symptoms after 8 years.
These results suggested that “negative symptoms may be an
important early course target for interventions to promote the
recovery” (75). Demjaha et al. (8) performed a longitudinal
study in a large cohort of 323 FEP patients that were studied
for 10 years of follow-up. Findings showed that the strongest
effect on treatment resistance was exercised by the negative
symptoms at onset of illness. Other predictors of non-response
and resistance in this study were the younger age of onset and
the diagnosis of schizophrenia. Yoshimura et al. (76) confirmed
the previous results about the influence of negative symptoms
on resistance in 131 patients with schizophrenia. Investigation
conducted by Downs et al. (77) in 638 subjects with early-
onset psychosis highlighted the importance of the negative
symptomatology in predicting response also in particular
populations such as children and adolescents. In fact, authors
concluded that early psychosis is characterized by negative
symptoms that significantly contributed to the unsuccessful
response or resistance to treatment. Other investigators evaluated
the predictors of remission in schizophrenia spectrum disorders.
Some of them (78) observed that a lower degree of positive,
negative, and general symptoms was linked with remission, while
other (62) found that only a lower degree of negative symptoms
at baseline was responsible of a better response to treatment.
Cognitive performances and disorganized symptoms obtained
less attention among investigators and few studies have been
performed on this issue. Chiliza et al. (7) concluded that both
cognitive and disorganized symptomatology predicted resistance
in 126 patients with schizophrenia spectrum disorders. Other
Levine and Rabinowitz (47) identified only cognitive impairment
at baseline as predictor of non-response to treatment in 49 FEP
patients with schizophrenia spectrum disorders. This finding is in
accordance a more recent study (16) in which authors compared
resistant and responder schizophrenic patients and observed that
resistant subjects had more severe cognitive impairment than
responders, in particular in verbal memory tasks.
Two illness-related factors that received particular attention
in the context of resistance to treatment are the diagnosis
of schizophrenia and the age at onset of disease. Some
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studies considered both these factors as predictors of non-
response (8, 41, 47). Other investigations found a significant
association only between diagnosis of schizophrenia and
treatment resistance (49, 70, 79).
Comorbidity is another clinical factor that we need to
consider in this context. In particular, substance use disorders
had a significant impact in terms of clinical manifestations
and treatment outcome. Around 40% of individuals with
schizophrenia spectrum disorders meet criteria for alcohol
use, and about 30% for substance use disorders (80). To our
knowledge only 5 studies evaluated how substance use may
predict outcome in schizophrenia spectrum disorders. The first
was a 30 months follow-up study (54) and involved 125 FEP
patients with schizophrenia spectrum disorders. Results showed
that the conjunction of male gender and substance abuse
(cannabis) was a predominant predictor of non-response to
treatment in this population. Pelayo-Terán et al. (81) confirmed
these findings in a 6-weeks study on 161 FEP patients with
schizophreniform and schizoaffective disorders, specifying that
misuse of cannabis predicted non-response of both positive and
negative symptoms. Studies performed by Austin et al. (70)
and Wimberley et al. (49) confirmed the role of substance use
disorders in treatment resistance in patients with FEP. The design
of these investigations was previously described in this review.
Boter et al. (82) in a 12-months follow-up study considered
this topic from another point of view and investigated predictors
of remission in 498 FEP patients with schizophreniform or
schizoaffective disorder. They identified the absence of substance
use disorder as predictor of remission.
Neurobiological Predictors of Treatment
Resistance
One of the controversies in literature concerned whether
psychosis onset derives by some neurobiological abnormalities
or whether it exerts a long-term toxic effect on the brain per
se. We have limited knowledge to identify which neurobiological
factors allow to separate from the FEP responders and resistant
patients. Anyway, some neurobiological and neuroimaging
factorsmay be detected as potentially involved in themechanisms
of response/non-response to therapies. Some experts have
suggested that patients with FEP present a variability in response
to antipsychotics that is induced by different neurobiological
correlates. One of the hypotheses concerns the relationship
between the activity of dopamine system and treatment response.
Some findings support this hypothesis as they found high levels
of synthesis and release of dopamine in schizophrenic patients
with a good response, in comparison with resistant subjects (83).
Some studies examined in plasma the level of dopamine
metabolites and observed that a lower concentration before
treatment is related to a less favorable response to first-line
medications (84, 85). Moreover, a study conducted post-mortem
compared two groups with positive and negative response
to treatment and identified a lower number of dopaminergic
synapses in patients with poor response.
Kim et al. (86) performed a small study including 12 patients
with schizophrenia who received clozapine and were considered
resistant, 12 patients who had considered responders, and 12
controls with no psychiatric diagnosis. Authors found that the
subgroup of resistant patients were distinguished by reduced
level of dopamine synthesis in striatum. This findings may
suggest that some neurobiological factors may be responsible for
treatment resistance in schizophrenia and a candidate biomarker
of response is the level of that dopamine synthesis.
In another recent study (87) authors reported that a greater
decrease of myelination in substantia nigra was observed in
cases of schizophrenia with a poor response to treatment in
comparison with responders and healthy controls. This finding
does not allow to conclude that substantia nigra aberrations may
be considered as predictors of treatment resistance. In fact, these
aberrations could be explained at least in part as a consequence of
toxicity of relapses and non-response to therapies. Nevertheless,
this investigation indicates the effort of investigators to better
understand, also in terms of neurobiological abnormalities the
treatment resistance phenomena.
Alterations in the levels of cortisol and other markers of
inflammations have been registered at the onset of psychosis.
Mondelli et al. (88) performed a 12 weeks follow-up study on
68 FEP patients and 57 controls. Authors collected saliva and
blood samples to measure the level of cortisol and serummarkers
of inflammations before and after antipsychotic administration.
Results showed that blunted cortisol awakening response
and increased proinflammatory cytokines were predictors of
resistance in the early phases of psychosis. These factors are
potentially considered as strong predictive factors of non-
response in this phase of the illness.
Regulatory system of cortisol was already found implicated
in schizophrenia treatment resistance in previous studies. For
example, pituitary volume measured at the onset of psychotic
disorders was investigated as a factor that can predict response
in FEP (89). Authors evaluated if baseline pituitary volume was
significantly related to treatment response in 42 FEP patients
treated with quetiapine for 12 weeks. Results indicated that
pituitary volume had an inverse relation with decrease of
symptom severity. This association highlighted the relevance
of hypothalamic-pituitary-adrenal axis in the early stages
of psychosis.
In recent years, neuroimaging techniques have allowed
to study if there is a relationship in psychotic disorders
between refractoriness to therapies and structures of brain.
Some investigators sustained that poor treatment response is
significantly related to the diminished volume of graymatter (90).
In one-hundred-twenty-six patients, including 80 subjects with
a diagnosis of first-episode psychosis, gyrification was measured
in multiple areas of brain and a significant hypogyria was found
in comparison with 46 healthy subjects. In particular, subjects
who did not respond to treatment showed hypogyria in bilateral
insular regions, left frontal area, and right temporal area when
compared with patients who responded. So, authors concluded
that at first stages of illness non-responders had significant
alterations of cortical folding compared with responders and with
healthy subjects. Due to the scarcity of investigations on this field
it is not possible to draw any conclusion. Nevertheless, it seems
that the pituitary volume measured with structural magnetic
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TABLE 1 | Summary of studies on predictive factors of treatment resistance.
Study design Patients (n)/type Trial duration Predictors of
PATIENT-RELATED FACTORS
Malla et al. (44) Longitudinal study 107 FEP SZ 2 years Response/remission
Better premorbid adjustment
Emsley et al. (45) Longitudinal study 57 FEP SSD 2 years Non-response/resistance
Single status, lower premorbid functioning
Crespo-Facorro et al.
(40)
RCT olanzapine vs. haloperidol
vs. risperidone
172 FEP SSD 6 weeks acute phase (in the context
of 3 years longitudinal intervention)
Non-response/resistance lower
premorbid functioning
Selten et al. (54) Longitudinal study 125 FEP SZ 30 months Non-response/resistance
Male gender (plus substance use)
Albert et al. (43) Longitudinal study 255 FEP 5 years Response/remission
Female gender, higher age, good
premorbid function
Addington and
Addington (42)
Longitudinal study 240 FEP SSD 36 months Non-response/resistance Reduced
social functioning and lower premorbid
functioning
Levine et al. (46) Longitudinal study 263 SSD at recent
onset
2 years Response/remission
Good premorbid functioning
Derks et al. (55) Randomized, open-label
,prospective study olanzapine vs.
haloperidol vs. risperidone
498 FEP SSD 1 year Non-response/resistance
Male gender
Verma et al. (50) Naturalistic study 1,175 FEP SSD 2 years Response/remission
Female gender, tertiary education
Teferra et al. (65) Longitudinal study 312 FEP SZ 5 years Response/remission
Single status
Crespo-Facorro et al.
(41)
RCT olanzapine vs. haloperidol
vs. risperidone
375 FEP SSD 6 weeks Non-response/resistance
Poorer premorbid adjustment
Díaz et al. (51) Randomized, open-label
,prospective study olanzapine vs.
haloperidol vs. risperidone
174 FEP SSD 1 year Non-response/resistance
Male gender, single status, and low
education level
Zhang et al. (53) Prospective cohort study 398 FEP SZ 1 year Response/remission
Higher age
Di Capite et al. (52) Longitudinal study 63 FEP SSD
antipsychotic
discontinuation
1 year Non-response/resistance
Male gender
Not related with educational level
Wimberley et al. (49) Cohort study 8,624 SZ at first
hospital contact
9 years Non-response/resistance
Younger age, living in less urban area, low
education level
Lally et al. (56) Longitudinal study 246 FEP SSD 5 years Non-response/resistance
Male gender
Lasalvia et al. (48) Retrospective study 444 FEP SSD 9 months Response/remission
Good premorbid adjustment and insight
regardless of treatment, higher educational
level
Friis et al. (79) Longitudinal study 301 FEP SSD 10 years Non-response/resistance
Lower premorbid functioning
DISEASE-RELATED FACTORS
Lambert et al. (69) Retrospective study 367 FEP SSD 18 months Non-response/resistance
High positive symptoms
Milev et al. (67) Longitudinal study 99 FEP SSD 7 years Non-response/resistance
Cognitive and negative symptoms
Siegel et al. (74) longitudinal study 208 FEP SZ 2–8 years (mean 3 years) Non-response/resistance
High positive, negative, and depressive
symptoms
Selten et al. (54) Longitudinal study 125 FEP SZ 30 months Non-response/resistance
Substance use
Addington and
Addinton (42)
Longitudinal study 240 FEP SSD 36 months Non-response/resistance
High positive and negative symptoms
(Continued)
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TABLE 1 | Continued
Study design Patients (n)/type Trial duration Predictors of
Boter et al. (82) Longitudinal study 498 FEP SSD 1 year Response/remission
Absence of use disorder
Strauss et al. (72) Longitudinal study 56 FEP SZ 20 years Non-response/resistance
Deficit syndrome
Levine and
Rabinowitz (47)
Longitudinal study 49 FEP SSD 2 years Non-response/resistance
Cognitive impairment
Diagnosis of schizophrenia
Early age at onset
Üçok et al. (62) Longitudinal study 93 FEP SZ 2 years Response/remission
High positive and low negative symptoms
at onset
Galderisi et al. (73) RCT olanzapine vs. amisulpride
vs. ziprasidone vs. quetiapina
345 FEP SSD 1 year Non-response/resistance
Persistent negative symptoms
Verma et al. (50) Naturalistic study 1,175 FEP SSD 2 years Non-response/resistance
Diagnosis of schizophrenia
Crespo-Facorro et al.
(41)
RCT olanzapine vs. haloperidol
vs. risperidone
375 FEP SSD 6 weeks Non-response/resistance
High positive and disorganized symptoms,
diagnosis of schizophrenia, and early age
at onset
Gaebel et al. (78) RCT risperidone vs. haloperidol 166 FEP SZ 1 year Response/remission
Low positive and negative symptoms
Pelayo-Terán et al.
(81)
RCT risperidone vs. haloperidol 161 FEP SSD 6 weeks Non-response/resistance
Cannabis use
Austin et al. (70) longitudinal study 496 FEP SSD 10 years Non-response/resistance
Negative symptoms
Substance use
Chiliza et al. (7) Longitudinal study 126 FEP SSD 1 year Non-response/resistance
High negative symptoms
Ventura et al. (75) Longitudinal study 146 SZ recent
onset
1 year + 7 years of follow-up Non-response/resistance
Early negative symptoms
Friis et al. (79) Longitudinal study 301 FEP SSD 10 years Non-response/resistance
Diagnosis of schizophrenia
Wimberley et al. (49) Cohort study 8,624 SZ at first
hospital contact
9 years Non-response/resistance
Diagnosis of schizophrenia
Substance use
Demjaha et al. (8) Longitudinal study 323 FEP SSD 10 years Non-response/resistance
Negative symptoms at onset diagnosis of
schizophrenia and early age at onset
Yoshimura et al. (76) Retrospective study 131 FEP SZ Not reported Non-response/resistance
High negative symptoms
Downs et al. (77) Cohort study 638 early-onset
psychosis (10–17
years)
5 years Non-response/resistance
High negative symptoms
NEUROBIOLOGICAL FACTORS
Garner et al. (89) Controlled dose-finding study 42 FEP SZ with
quetiapine
12 weeks Non-response/resistance
Larger pituitary volume
Palaniyappan et al.
(90)
Case-control study 126 (80 FEP) SSD 12 weeks Non-response/resistance
Hypogyria at bilateral insular, left frontal,
and right temporal regions
Mondelli et al. (88) Longitudinal study 68 FEP
57 controls
12 weeks Non-response/resistance
Blunted cortisol awakening response and
increased proinflammatory cytokines
Kim et al. (86) RCT 12 SZ—TR with
clozapine vs. 12
SZ responders vs.
12 healthy controls
12 weeks Non-response/resistance
Lower dopamine synthesis capacity in
striatum
(Continued)
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TABLE 1 | Continued
Study design Patients (n)/type Trial duration Predictors of
Walker et al. (87) RCT (post-mortem) 14 SZ (6 TR)
9 healthy controls
Not available Non-response/resistance
Reduction of myelination in substantia
nigra
TREATMENT-RELATED FACTORS
Bottlender et al. (101) Longitudinal study 58 FEP SZ 15 years Non-response/resistance
Longer DUP
Correll et al. (93) Open-label study 131 acute SSD
with fluphenazine
4 weeks Non-response/resistance
Poor response at week 1
Malla et al. (44) Longitudinal study 107 FEP SZ 2 years Response/remission
Higher level of adherence
Leucht et al. (94, 95) Data analysis from 7 RCTs 1,708 SSD Not available Non-response/resistance
Poor response at week 1 and 2
Kinon et al. (26) Data analysis from 5 RCTs 1,077 SSD 6 months Non-response/resistance
Poor early response (but early response
does not predict subsequent response)
Boter et al. (82) Longitudinal study 498 FEP SSD 1 year Response/remission
Higher level of adherence
Kinon et al. (96) RCT 628 SSD with
risperidone. If non
response switch to
olanzapine
12 weeks + 10 weeks if non early
response
Non-response/resistance
Poor response within 2 weeks
Üçok et al. (62) Longitudinal study 93 FEP SZ 2 years Response/remission
Higher level of adherence
Zhang et al. (53) Prospective cohort study 398 FEP SZ 1 year Response/remission
Higher level of adherence
Austin et al. (70) Longitudinal study 496 FEP SSD 10 years Non-response/resistance
Longer DUP
Friis et al. (79) Longitudinal study 301 FEP SSD 10 years Non-response/resistance
Longer DUP
Demjaha et al. (8) Longitudinal study 323 FEP SSD 10 years Non-response/resistance
Longer DUP
Yoshimura et al. (76) Retrospective study 131 FEP SZ Not reported Response/remission
Shorter DUP
SZ, schizophrenia; SSD, schizophrenia spectrum disorders; FEP, first episode of psychosis; TR, treatment resistant; RCT, randomized-controlled study; DUP, duration of
untreated psychosis.
resonance may represent a potential predictor of response/non-
response in psychosis at onset.
Treatment-Related Predictors of
Resistance
In our opinion three factors related to treatment are particularly
relevant in predicting resistance in schizophrenia and require
to be mentioned and discussed: adherence, early response,
and duration of untreated psychosis. Concerning adherence to
therapies, antipsychotic treatment non-adherence was found
tightly linked to low odds for response and remission, in
particular in the first stages of illness (20, 22, 52, 91). Some
Pelayo-Terán et al. (81) suggested that adherence was one of
the most robust predictors of the first relapse. The main studies
on this topic were in accordance to conclude that an higher
level of adherence since FEP predicted response and remission
of the illness (44, 53, 62, 82). In light of these considerations,
prescription of long-acting antipsychotics in patients with several
risk factors for relapse (for example diagnosis of schizophrenia,
comorbid substances abuse, prominent negative symptoms, and
non-adherence to oral antispychotics) also at first-episode of
psychosis may significantly improve outcome of FEP (22).
Response to antipsychotic treatments should begin within
first weeks of therapy, with the greatest effect in the first 2
weeks (24, 92). Correll et al. (93) performed an open-label 4-
weeks study in 131 patients with schizophrenia who received
fluphenazine. They showed that poor response in the first week
of treatment with a typical antipsychotic may predict non-
response also at fourth week of the trial. The same results
were obtained by Leucht et al. (94, 95) who analyzed data
from 1708 patients with schizophrenia or schizophreniform
disorder enrolled in 7 randomized controlled trials (RCT) on
antipsychotics. In addition, these authors stated that minimal
symptoms reduction at week 2 had high specificity and sensitivity
in identifying responders at week 4. This datum was also
confirmed by Samara et al. (27) in a meta-analysis of 34 studies
aimed to evaluate the association between lack of symptoms
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improvement at week 2 and later non-response. Kinon and
collaborators conducted two investigations (26, 96). In the first
one, authors analyzed data from 5 double-blind RCTs including
1,077 patients with schizophrenia spectrum disorders who
received second-generation antipsychotics. Authors considered
a period of observation of 6 months and assessed at different
time points medication discontinuation rates. Results showed
that early non-response predicted subsequent lack of response,
but early response could not be considered as a predictor of
following response. The same Kinon et al. (26) performed a
12-weeks RCT aimed to investigate in 628 patients diagnosed
with schizophrenia or schizoaffective disorder who initially
received risperidone whether the early response (within 2
weeks) to an antipsychotic medication may predict the following
response. Subjects who responded proceeded with risperidone,
while patients who did not respond in the first 2 weeks
were randomized to continue with risperidone or to receive
olanzapine for other 10 weeks. Findings reported that early
non-responders may require more than 4–6 weeks to respond
to antipsychotics.
Another important variable associated with non-response
and resistance is the duration of untreated psychosis (DUP).
DUP is “the period between the time psychosis begins to
the time adequate treatment is sought and secured. The
mean duration of untreated psychosis is ranged between 1
and 2 years and the median is about 6 months” (97). A
more prolonged DUP has been related to a longer time of
response to treatment in patients who presented a first-episode
of psychosis and to an impaired course of the disorder (21,
98–100). Bottlender et al. (101) conducted a long-term study
lasting 15 years in 58 patients with schizophrenia followed-up
since their first psychiatric admission. Authors observed that a
higher level of negative, positive and general psychopathological
symptoms and a lower global functioning 15 years after the
first psychiatric admission were associated with a prolonged
DUP. In accordance with these results, another 10-years
follow-up study (70) concluded that a longer DUP predicted
worse trajectories of positive and negative symptoms in time,
with a poor response to medications. Friis et al. (79) stated
that first-episode psychosis patients that have not begun an
adequate antipsychotic treatment at least within 6 months
(having a longer DUP) presented an higher risk to become
resistant patients. In line with previous findings, Demjaha et al.
(8) reported that longer DUP predicted treatment resistance.
Moreover, Yoshimura et al. (76) found that a shorter DUP
predicted favorable response and remission in FEP patients
with schizophrenia.
All literature findings highlighted the importance to detect
psychosis at onset and to early consider treatment-related factors
because they are modifiable risk variables.
DISCUSSIONS
There is a general consensus among authors in retaining that the
identification of specific factors predicting treatment response
in patients with FEP significantly ameliorates the quality of
clinical management of these patients in the critical early phase of
pathology. Adequate early interventions produce a positive effect
on long-term illness outcome, in terms of remission and recovery.
Main findings of our review show that among patient-
related predictors of resistance to treatment lower premorbid
functioning is an important factor in distinguishing antipsychotic
non-responders from responders. Lower educational level can
be also considered as a robust predictor of resistance, while the
role of age and marital status is still controversial. Several studies
suggest the male gender as a potential risk factor for treatment
non-response, but we have to consider that many other studies
have not confirmed the effect of gender.
Regarding disease-related predictors of treatment resistance,
the higher level of negative symptoms from the FEP and their
persistency over time induces a worse impairment of social
functioning, more serious psychopathological phenomena, and a
higher degree of refractoriness to treatment then controls who
present a progressive decrease of negative symptoms. Positive,
disorganized, and cognitive symptoms seem to be less significant
in predicting treatment response. According to our review,
the two main predictors of resistance related to the disorder
are the diagnosis of schizophrenia and the younger age at
onset. Among comorbidity conditions substance use disorder is
the most studied predictive factor of treatment resistance and
poor outcome.
Some neurobiological and neuroimaging factors may be
identified as potentially involved in the mechanisms of
response/non-response to therapies, but none of these factors has
been identified as reliable predictor that can allow to separate
responders and resistant patients in the course of the FEP.
Some literature data support the hypothesis that the level of the
dopamine synthesis is a potential biomarker of responsiveness
to treatment. In addition, blunted cortisol awakening response
and higher concentrations of pro-inflammatory cytokines are
biological predictive factors of treatment resistance in early
stages of psychotic disorders. Some neuroimaging studies show
that at first stages of illness patients who do not respond
have a significant reduction of pituitary volume and defects
of cortical folding. Few innovative investigations have explored
potential genetic predictors of treatment resistance, but initial
data do not allow to draw any conclusion. Genetic studies about
response to medications in early phases of psychosis are required,
considering that only few initial investigations with inconclusive
results are available.
TABLE 2 | Clinical predictive factors of treatment resistance.
Stable factors Changeable
Poor premorbid functioning Lower educational level
Male gender Single marital status
Younger age at onset Negative symptoms
Diagnosis of schizophrenia Substance use disorder
Neurobiological factors Non-adherence
Early non-response (within week 2)
Duration of untreated psychosis
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Finally, lack of adherence to prescriptions, no early response
(within 2 weeks) to antipsychotics, and prolonged of duration
of untreated psychosis are the most important treatment-related
factors that predict resistance.
Data provided from cited studies are displayed in Tables 1, 2.
CONCLUSIONS AND REMARKS FROM
THE SYSTEMATIC REVIEWS
In literature we have examined five systematic reviews that
focus on the topics of our investigation and can contribute to
support our conclusions (20, 21, 32, 102, 103). In summary,
these studies demonstrate that outcomes for patients with
schizophrenia spectrum disorders can be significantly improved
ameliorating early treatments and shortening the period of time
that divides the beginning of symptoms from adequate specific
interventions. Authors highlight that available trials are affected
by some criticalities that are at least partly responsible for the
heterogeneity of findings. For example, studies vary considerably
in defining diagnosis of patients who can be enrolled (some
authors include subjects with unspecified psychosis or brief
psychotic disorder that can present a completely different course
and outcome from schizophrenia). The diagnostic instability
intrinsic to first episode has to be considered as potential bias for
the results of investigations. In addition, few studies are designed
with a sufficient statistical power to measure the predictive effect
of several clinical factors with respect to treatment response.
Studies have different duration and frequency of assessments
during follow-up. Another very important limitation is that, as
we have explained in the introduction of this review, criteria for
determining resistance are different among studies, sometimes
limited to severity of symptoms, in other cases extended to
cognitive performances and social functioning. Despite these
limitations and persisting uncertainty on the actual role of most
clinical and biological factors, there is no doubt that developing
research and refining knowledge on predictors of response in the
early stage of psychotic disorders can produce noticeable results
in terms of improvement of long-term clinical and functional
outcome. In particular, some key predictive factors, like duration
of untreated psychosis, or non-adherence to medications, can
be modified by early intervention with significant effects on
long-term outcome.
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